System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Giuseppe Curigliano is an expert in Oncology at IRCCS Ospedale San Raffaele (Italy). As of October 2026, ScienceLeadR ranks Giuseppe Curigliano in the top 1% of experts worldwide for Breast Neoplasms, Breast Diseases and Bronchial Neoplasms. Giuseppe Curigliano has authored 1,518 publications, the most recent in 2026, and is an investigator in 106 clinical trials, 45 of them ongoing. SLR score: 7,824 (community average: 125). How the SLR is computed.

LeadR Profile

Giuseppe Curigliano IRCCS Ospedale San Raffaele Italy
7 824 ScienceLeadR Reputation 7824

Unlock

Register Login
Network Map

Oncology

Subspecialties: Dermatology - Pharmacy - Biochemistry

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2001 - 2026
Source: PubMed

European Institute of Oncology

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 1518

Citations

Citations: 63 682 1st author: 112 Last author: 366 Unique author: 35

Main journals

Ann Oncol 230
J Clin Oncol 126
ESMO Open 124
Cancer Res 101
Eur J Cancer 86

Best Journals

Ann Oncol 143
J Clin Oncol 84
Lancet Oncol 20

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Tailoring adjuvant endocrine therapy in patients with estrogen receptor-low breast cancer.
PMID 42932238 — estrogens, breast neoplasms, receptors, estrogen, neoplasms, breast, therapeutics		J Natl Cancer Inst20260
Outcomes of elacestrant in patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer who received prior endocrine therapy and cyclin-dependent kinase inhibitor in a real-world setting.
PMID 42735454 — breast neoplasms, neoplasms, cyclin-dependent kinases, cyclins, neoplasm metastasis, breast, therapeutics		ESMO Open20260
Prognostic value of hormone receptor expression in patients with HR+/HER2- advanced BC treated with first-line ET+CDK4/6i: results from the multicentre observational, real-world PALMARES-2 study.
PMID 42872060 — hormones, therapeutics		EClinicalMedicine20260
Electronic patient-reported outcomes platforms to shift from episodic to continuous oncology in breast cancer.
PMID 42823197 — breast neoplasms, neoplasms, breast, patient reported outcome measures		Curr Opin Oncol20260
Beyond poly(ADP-ribose) polymerase inhibition: emerging therapeutic strategies for germline BRCA1/2 -mutated and PALB2 -mutated breast cancers.
PMID 42762135 — genes, recombination, genetic, poly(adp-ribose) polymerases, homologous recombination, breast neoplasms, pharmaceutical preparations, neoplasms, synthetic lethal mutations, ribose, poly adenosine diphosphate ribose, biomarkers, breast, therapeutics, genes, brca1, adenosine diphosphate ribose		Curr Opin Oncol20260

Clinical Studies 106

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 10

By phase:

Phase 1 28
Phase 2 25
Phase 1/Phase 2 24
Phase 3 15
N/A 14

By status:

Recruiting 39
Completed 32
Active not recruiting 16
Terminated 13
Not yet recruiting 3
Unknown 3

By type:

Interventional 97
Observational 9

By Monocentric/Multicentric:

monocentric 15
multicentric2to4 3
multicentric5to9 12
multicentricup10 76

Main Topics

Cohort/Consortium Investigators 3

Ongoing Clinical Trials

45 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Clinical study to test the safety tolerance and preliminary efficacy of oral ITF3756 administered alone or in combination with an anti protein 4 agent associated with cytotoxic T lymphocytes in patients with advanced solid tumors
2022-501089-22-00 — safety, lymphocytes, neoplasms, t-lymphocytes, cytotoxic, t-lymphocytes		Phase 1Active not recruiting2022
A study to test if different doses of D3S 001 used on its own or in combination with other anti cancer medicines is safe and tolerable in people with advanced solid tumours with KRAS p G12C modification
2023-508517-16-00 — safety, neoplasms, therapeutics, mutation, pharmacokinetics		Phase 1/Phase 2Recruiting2024
Beamion BCGC 1 A study to find a suitable dose of zongertinib used alone and in combination with other treatments to test whether it helps people with different types of HER2 cancer that has spread
2023-509566-38-00 — breast neoplasms, esophagogastric junction, neoplasms, adenocarcinoma, breast, therapeutics, colorectal neoplasms, capecitabine, trastuzumab		Phase 1/Phase 2Recruiting2024
A clinical trial to learn how liver function affects the blood levels of DAK539 in people with advanced cancer
2025-521001-40-00 — blood, neoplasms, liver		Phase 1Recruiting2026
A Study of Dato DXd in Inoperable or Metastatic Hormone Receptor positive HER2 IHC 0 Breast Cancer
2025-521904-23-00 — safety, breast neoplasms, neoplasms, hormones, breast, therapeutics		Phase 2Recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS